CAJ | 학술논문

目的：探讨罗格列酮治疗对腹膜透析患者微炎症状态的影响。方法：收集我院持续性腹膜透析患者50例,随机分为两组,治疗组患者给予常规腹膜透析及罗格列酮4 mg·d-1,对照组常规腹膜透析治疗,两组均治疗12周。观察两组患者治疗前后空腹血糖( FBG)、糖化血红蛋白、血红蛋白、血清总胆固醇、高密度脂蛋白胆固醇( HDL-C)、低密度脂蛋白胆固醇、三酰甘油、高敏C反应蛋白(hs-CRP),肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、胰岛素抵抗指数(HOMA-IR)等指标变化。结果：治疗12周后,两组患者血FPG、HOMA-IR、hs-CRP、TNF-α、IL-6水平均有明显下降,HDL-C水平有明显升高,且与对照组比较差异具有统计学意义(P<0.05)。结论：罗格列酮可改善腹膜透析患者微炎症反应状态及胰岛素抵抗,纠正脂代谢紊乱。
목적：탐토라격렬동치료대복막투석환자미염증상태적영향。방법：수집아원지속성복막투석환자50례,수궤분위량조,치료조환자급여상규복막투석급라격렬동4 mg·d-1,대조조상규복막투석치료,량조균치료12주。관찰량조환자치료전후공복혈당( FBG)、당화혈홍단백、혈홍단백、혈청총담고순、고밀도지단백담고순( HDL-C)、저밀도지단백담고순、삼선감유、고민C반응단백(hs-CRP),종류배사인자α(TNF-α)、백세포개소6(IL-6)、이도소저항지수(HOMA-IR)등지표변화。결과：치료12주후,량조환자혈FPG、HOMA-IR、hs-CRP、TNF-α、IL-6수평균유명현하강,HDL-C수평유명현승고,차여대조조비교차이구유통계학의의(P<0.05)。결론：라격렬동가개선복막투석환자미염증반응상태급이도소저항,규정지대사문란。
Objective:To assess the effect of rosiglitazone on inflammation in peritoneal dialysis patients. Methods:Fifty patients undergoing continuous ambulatory peritoneal dialysis were collected in our hospital. The treatment group was assigned to receive regular peritoneal dialysis and rosiglitazone 4mg once daily while the control group was received regular peritoneal dialysis for 12 weeks. Such serum examinations as fasting blood glucose (FBG), glycosylated hemoglobin A1c, haemoglobin, serum total cholesterol, high density lipoprotein cholesterol(HDL-C), low density lipoprotein cholesterol, triglycerides and high sensitivity C reactive protein (hs-CRP) were measured, tumor necrosis factorα(TNF-α) and interleukin-6 (IL-6) levels were measured by ELISA, and homeostasis model as-sessment of insulin resistance( HOMA-IR) was also evaluated before and after the treatment. Results:After the 12-week treatment by rosiglitazone, the levels of FPG, HOMA-IR, hs-CRP, TNF-αand IL-6 were declined significantly(P<0. 05), and the level of HDL-C was increased significantly(P<0. 05). Conclusion: Rosiglitazone shows significant anti-inflammatory, insulin resistance improve-ment and anti-lipidemic effects in peritoneal dialysis patients.